Presentation

Trefoil provided an update on the company and its clinical program for TTHX1114 at the inaugural Eyecelerator 2020 virtual conference on November 6. TTHX1114 is the company’s first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases. 

Trefoil Therapeutics presents accelerated healing of corneal endothelial lesions by engineered fibroblast growth factor at ARVO 2020.